Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Adrenocortical Carcinoma 2Zollinger-Ellison Syndrome 1Wilms Tumor 1Somatostatinoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Paraganglioma 1Osteosarcoma 1Neuroendocrine Tumors 1Neuroectodermal Tumors 1Neuroblastoma 1Neoplasm Metastasis 1Insulinoma 1Hepatoblastoma 1Glucagonoma 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Carcinoma, Islet Cell 1Carcinoma 1Carcinoid Tumor 1

Interventions

Nivolumab 2tipifarnib 1olaparib 1lutetium Lu 177 dotatate 1fludarabine 1entinostat 1cixutumumab 1cabozantinib 1aldesleukin 1Quality of Life 1Patient Reported Outcome Measures 1Oxaliplatin 1Molecular Diagnostic Techniques 1LY2940680 1Ipilimumab 1Immunotherapy 1Fentanyl 1Drug Therapy 1Cyclophosphamide 1CTLA-4 Antigen 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × cixutumumab × Endocrine × Clear all
NCT00831844 2015-03-30

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 2 Completed
116 enrolled 8 charts
CNSEndocrineGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Hepatoblastoma, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡